Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cellular and mitochondrial reactive oxygen species (ROS) generation machinery is a complex network of enzymes and organelles responsible for producing reactive oxygen intermediates like superoxide and hydrogen peroxide (Murphy, 2009; Zorov et al., 2014). Key components include the mitochondrial electron transport chain (ETC), particularly Complexes I and III, where electron leakage results in the premature reduction of molecular oxygen (Murphy, 2009). Additionally, the NADPH oxidase (NOX) family of enzymes plays a specialized role in generating ROS for signaling and host defense (Bedard & Krause, 2007). Other significant contributors include xanthine oxidase, monoamine oxidase, and various peroxisomal and endoplasmic reticulum enzymes (Holmström & Finkel, 2014). Under physiological conditions, this machinery regulates essential signaling pathways, including cell growth, differentiation, and the immune response (Schieber & Chandel, 2014). However, dysregulation of these systems leads to excessive ROS production, causing oxidative stress and subsequent damage to cellular macromolecules such as DNA, proteins, and lipids (Sies & Jones, 2020). This oxidative damage is a hallmark of numerous pathologies, including neurodegenerative diseases, cardiovascular disorders, and cancer (Barnham et al., 2004). Therapeutic strategies targeting this machinery involve the use of site-specific inhibitors, such as NOX inhibitors, or mitochondria-targeted antioxidants like MitoQ that scavenge ROS at the site of production (Smith et al., 2012; Teixeira et al., 2013). Balancing the modulation of this machinery is critical, as complete suppression can interfere with vital redox-sensitive signaling and immune functions (Lambeth, 2004).
Drugs targeting this machinery typically act by inhibiting specific ROS-producing enzymes, such as NADPH oxidases (NOX), or by utilizing mitochondria-targeted antioxidants to neutralize reactive species at their source (Smith et al., 2012; Teixeira et al., 2013). Some agents also work by uncoupling the electron transport chain or enhancing the activity of endogenous antioxidant systems to mitigate the effects of electron leakage (Murphy, 2009).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cellular and mitochondrial reactive oxygen species generation machinery (ROS generation machinery).